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ABSTRACT 
Protein conformational changes due to cofactor binding (e.g. metal ions, heme) and/or 
posttranslational modifications (e.g. phosphorylation) modulate dynamic protein complexes.  
Calmodulin (CaM) plays an essential role in regulating calcium (Ca2+) signaling and 
homeostasis. No systematic approach on the identification of phosphorylation-dependent 
Ca2+/CaM binding proteins has been published. Herein, we report a proteome-wide study of 
phosphorylation-dependent CaM binding proteins from mammalian cells. This method, termed 
“Dynamic Phosphoprotein Complex Trapping”, “DPPC Trapping” for short, utilizes a 
combination of in vivo and in vitro assays. The basic strategy is to drastically shift the 
equilibrium towards endogenous phosphorylation of Ser, Thr, and Tyr at the global scale by 
inhibiting corresponding phosphatases in vivo. The phosphorylation-dependent calmodulin-
binding proteins are then trapped in vitro in a Ca2+-dependent manner by CaM-Sepharose 
chromatography. Finally, the isolated calmodulin-binding proteins are separated by SDS-PAGE 
and identified by LC/MS/MS. In parallel, the phosphorylation-dependent binding is visualized 
by silver staining and/or Western blotting. Using this method, we selectively identified over 120 
CaM-associated proteins including many previously uncharacterized. We verified ubiquitin-
protein ligase EDD1, inositol 1, 4, 5-triphosphate receptor type 1 (IP3R1), and ATP-dependent 
RNA helicase DEAD box protein 3 (DDX3), as phosphorylation-dependent CaM binding 
proteins.  To demonstrate the utilities of our method in understanding biological pathways, we 
showed that pSer/Thr of IP3R1 in vivo by staurosporine-sensitive kinase(s), but not by 
PKA/PKG/PKC, significantly reduced the affinity of its Ca2+-dependent CaM binding. However, 
pSer/Thr of IP3R1 did not substantially affect its Ca2+-indepedent CaM binding. We further 
showed that phosphatase PP1, but not PP2A or PP2B, plays a critical role in modulating the 
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phosphorylation-dependent CaM binding for IP3R1. If combined with other phosphoprotein and 
phosphopeptide enrichment techniques such as IMAC, our method may serve as a general 
strategy to identify and characterize phosphorylation-dependent and functionally important 
protein complexes in mammalian cells.  
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INTRODUCTION 
Metal ions and metalloproteins play important roles in regulating biological processes.1 
Calcium (Ca2+) is the central second messenger. Ca2+ homeostasis and signaling is inherently 
linked to a myriad of cellular processes including cell growth, differentiation, synaptic activity, 
neurotransmitter release, and neuronal degeneration.2 Calmodulin (CaM) is a ubiquitously 
expressed and highly conserved calcium regulatory protein. CaM binds up to four Ca2+ ions and 
interacts with its target proteins upon Ca2+ binding. Conformational changes occur in CaM upon 
its binding to Ca2+ and target proteins. Extensive research has been carried out to identify and 
characterize the Ca2+/CaM complexes. For example, an online database 
(http://calcium.uhnres.utoronto.ca) exists for CaM targets. A recent proteome-wide scanning by 
using an mRNA-displayed human proteome library have identified around 100 proteins that 
potentially interact with CaM in a Ca2+-dependent manner.3 
Protein-protein interactions are vital for all cellular functions. Affinity purification-mass 
spectrometry remains one of the most powerful tools for the discovery and characterization of 
protein complexes.4,5 Affinity approaches include classical immunoprecipitation, epitope-tagging 
with Flag or HA, GST-pull-down, and tandem affinity purification (TAP). Many protein 
interactions that are critical for cellular pathways are dynamic and tuned by posttranslational 
modifications. Thus, it is of the highest utility to have a means to “trap” dynamic complexes in 
order to identify and characterize them. Lowering the temperature has proven to be one of the 
most straightforward and generally applicable ways to trap protein complexes from 
hyperthermophilic Archaea like P. furiosus and S. solfataricus. However, more challenges 
remain for eukaryotic cells at ambient temperatures.   
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Protein phosphorylation and dephosphorylation at serine, threonine, and tyrosine are the 
predominant mechanisms of signal transduction in mammalian cells.6-8 A global analysis of 
protein phosphorylation in yeast has been published.9 Phosphorylation of CaM influences its 
binding to CaM-dependent proteins and results in important physiological consequences.10 On 
the other hand, phosphorylation of its partners also affects the binding. For example, a recent 
study showed that phosphorylation of a protein named regulator of calmodulin signaling (RCS) 
at Ser55 by PKA increased its binding to CaM and led to inhibition of CaM-dependent 
phosphatase 2B (PP2B, also called calcineurin).11 However, no systematic study on proteome-
wide CaM-binding phosphoproteins has been published. The major hurdle lies in the low 
abundance of endogenous phosphorylated forms and the lack of an efficient way to trap these 
dynamic phosphorylation-dependent complexes.  
We here describe a new strategy, termed “Dynamic Phosphoprotein Complex Trapping”, 
“DPPC Trapping” for short, to identify and characterize calcium- and phosphorylation-
dependent calmodulin complexes in mammalian cells. This method takes advantage of in vivo 
enrichment of endogenous phosphorylation of Ser, Thr, and Tyr, and in vitro trapping of the 
CaM complexes, followed by protein identification through LC/MS/MS. Our results demonstrate 
that “DPPC Trapping” is useful in identifying phosphorylation-dependent protein complexes and 
elucidating signaling pathways in mammalian cells. 
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EXPERIMENTAL PROCEDURES 
Cell Culture  
HeLa cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 10% (v/v) fetal bovine serum (FBS) and penicillin/streptomycin in a humidified atmosphere 
of 5% (v/v) CO2 at 37 °C. The cells were maintained overnight (16-18 hrs) in 1% FBS medium 
right before treatments. Cells with 70-80% confluency on 10 cm dishes were incubated with 100 
µM sodium pervanadate (PV) for 2 hr and 20 nM calyculin A (CLA) for 1hr, respectively. To 
prepare stock solution of 50 mM sodium pervanadate, 100 mM sodium orthovanadate was 
activated by mixing 1:1 with 100 mM hydrogen peroxide. The reaction was allowed to proceed 
for 15 min at room temperature and terminated by addition of 400 U/ml of catalase. For kinase 
inhibitor experiments, cells were either treated with the desired inhibitor alone, or preincubated 
with the inhibitor followed by co-treatment with the inhibitor and 20 nM calyculin A for 1hr.  
The duration and concentration for each kinase inhibitor was: 30 min for 10 nM, 50 nM, 200 nM 
or 1 µM staurosporine, 1 hr for 2 µM chelerythrine, or 50 µM H-89, or 5 µM HA-1077, or 1 
µΜ KT-5720, or 50 µM roscovitine. For protein phosphatase inhibitor experiments, the 
treatment was 1 hr for 10 µM cyclosporine A, or 200 nM okadaic acid, or 10 µM FK-506.  
Protein kinase inhibitors including staurosporine (nonspecific for pSer/Thr kinases), H-89 
(for PKA and PKG), chelerythrine (for PKC), HA-1077 (for Rho kinases), and roscovitine (for 
CDK1, 2, 5), were purchased from LC Labs, and KT-5720 (for PKA and phosphorylase) was 
from Calbiochem. Phosphatase inhibitors including calyculin A (for PP1 and PP2A), okadaic 
acid (for PP1 and PP2A), FK-506 (for PP2B), and cyclosporine A (for PP2B), were all purchased 
from LC Labs.   
 7
Sodium orthovanadate, hydrogen peroxide, and catalase were purchased from Sigma. 
Alkaline phosphatase was from New England Biolabs. Cell culture products and other 
consumable laboratory supplies were purchased from Fisher Scientific Corp. and VWR 
International. All other culture media and supplements were from Invitrogen. 
 
Calmodulin Chromatography and Immunoblotting Analysis 
HeLa cells were lysed with a lysis buffer containing 1% Triton X-100, 50 mM Tris–HCl 
(pH 7.5), 150 mM NaCl, 1 mM sodium pervanadate, 40 nM microcystin (Calbiochem), and 
protease inhibitor cocktails (Roche) in the presence of 2 mM CaCl2 or 2 mM EGTA. To 
investigate the effects of in vitro auto-dephosphorylation on the CaM binding of IP3R1, cells 
were lysed using buffers containing different combination of phosphatase inhibitors with other 
components remained unchanged. The conditions included pervanadate (PV) only, microcystin 
(MC) only, both of pervanadate and microcystin (PV+MC), in the absence of either inhibitor (-), 
and in the presence of alkaline phosphatase (AP, 50 unit/ml) only. The lysates were centrifuged 
at 15,000 rpm for 30 min at 4ºC by using a microcentrifuge. The protein concentration of the 
supernatants was quantified using the modified Bradford assay (Bio-Rad Laboratories). Resulted 
cell lysates were incubated at 4°C overnight with CaM Sepharose 4B beads (Amersham 
Biosciences) in the presence of 2 mM CaCl2 or 2 mM EGTA. Subsequently, CaM beads were 
washed three times with the lysis buffer. Finally, proteins captured on beads were eluted and 
resolved by SDS–PAGE using 4-20% gels (ISC BioExpress), and subjected to silver staining or 
Western blot analysis.  
For immunoblotting analysis, proteins separated on 4-20% gradient gels were transferred 
to a 0.45 µm nitrocellulose membrane (Bio-Rad Laboratories). The membrane was blocked with 
 8
5% nonfat milk, and incubated with the primary antibody in TBST buffer (25 mM Tris-HCl, pH 
7.4, 60 mM NaCl, and 0.075% Tween 20) containing 5% nonfat milk. The bound primary 
antibodies were detected by a goat anti-mouse or a goat anti-rabbit IgG-horseradish peroxidase 
conjugate (Santa Cruz Biotechnologies) and the ECL detection system (Amersham Biosciences). 
The immunoblotting results were scanned with an Umax 2100 high-resolution scanner (Umax 
Technologies).  The intensity of protein bands was quantified with ImageJ program (National 
Institutes of Health) and Student’s t-test was used for statistical analysis.  
The mouse monoclonal antibody against total actin (including all isoforms) was from 
Chemicon. The rabbit polyclonal anti-IP3R1 antibody and the mouse monoclonal anti-
phosphotyrosine (4G10) (p-Tyr) antibody were from Upstate. The rabbit polyclonal anti-
phospho-threonine (p-Thr) antibody was from Cell Signaling. The goat anti-EDD1 antibody was 
from Santa Cruz Biotechnologies. The rabbit anti-DDX3 was from Bethyl Laboratories Inc. 
 
In-Gel Digestion and Protein Identification 
To identify CaM binding proteins, we followed essentially the same procedures as we 
described in detail previously for protein identification.12  Briefly, a selected 22 silver-stained 
bands were excised from the gels and digested with trypsin. The tryptic peptides were extracted 
and subjected to LC/MS/MS analysis using a Q-TOF API US mass spectrometer (Waters Corp.) 
interfaced with a capillary liquid chromatography system (Waters Corp.). The LC eluent was 
directed to the electrospray source with a PicoTip emitter (New Objectives). Mass spectra were 
processed using MassLynx 4.0 software and proteins were identified using Protein Global Sever 
1.0/2.0 software. The protein identities were further confirmed by Mascot 
(http://www.matrixscience.com) using the MS/MS peak lists exported from MassLynx. The 
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NCBI non-redundant databases were used for the search. For proteins with only one peptide 
sequenced, two criteria were used in the final identification following manual interpretation of 
the MS/MS data: Mascot score is more than 50, and the relative protein mobility on SDS-PAGE 
gels fits its theoretical molecular weight. Protein modifications considered included 
carbamidomethylation of cysteine (fixed), N-terminal acetylation, N-terminal Gln to pyroGlu, 
oxidation of methionine and phosphorylation of serine, threonine and tyrosine.  
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RESULTS 
Calmodulin Binding was Ca2+-dependent as well as Phosphorylation-dependent  
Calyculin A (CLA) is a specific inhibitor for PP1 and PP2A, while pervanadate (PV) is a 
potent inhibitor for Tyr phosphatases. They have been used previously to increase in vivo global 
pSer/Thr and pTyr levels respectively.13,14 Total lysates of HeLa cells treated with pervanadate 
for 2 hours or Calyculin A for 1 hour were compared to those of control cells. Western blotting 
using antibody that recognizes pThr or pTyr clearly showed drastic increase in global pSer/Thr 
and pTyr levels after CLA and PV treatments respectively (Figure 1A). To demonstrate that 
global protein expression was unaffected and to be assured of equal loading of total proteins, we 
stained the immunoblot with a ponceau solution (data not shown) and probed it with anti-actin 
antibody afterwards. Figure 1A clearly demonstrated the equal amount of actin indicating that 
global protein expression remained unchanged under our treatment conditions.     
To identify phosphorylation-dependent CaM binding proteins, we carried out calmodulin 
chromatography in the presence of 2 mM CaCl2 or 2 mM EGTA. The CaM binding products 
were separated by SDS-PAGE and detected by silver staining (Figure 1B). Twenty-two silver-
stained bands labeled as 1 to 22 from the top to the bottom (Figure 1B) were selected for mass 
spectrometry analysis. These included Ca2+-independent (Band 1 and Band 6) and Ca2+-
dependent bands (the remaining ones). There were multiple bands that showed clear 
phosphorylation-dependent binding to CaM, with band 3, 4 and 19 being downregulated and 
band 9 being upregulated after CLA treatment. Immunoblotting analysis of a duplicate gel using 
pTyr and pTyr antibodies respectively demonstrated that a significant number of these Ca2+-
dependent CaM-associated proteins are either pThr or pTyr proteins (data not shown).  
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Mass Spectrometry Identified Diverse Classes of Calmodulin Binding Proteins  
All 22 silver-stained bands were identified successfully with high confidence using in-gel 
trypsin digestion followed by tandem mass spectrometry as described in Experimental 
Procedures. Majority of the bands contained more than one protein. For all the proteins 
identified, two search engines (ProteinLynx and Mascot) gave the same protein hits with high 
confident scores. A limited number of proteins were identified with only one peptide sequenced 
and manual interpretation of the MS/MS spectra (Mascot score > 50) was performed. In addition, 
the protein’s predicted molecular weight agreed well with its relative mobility on the SDS-PAGE 
gel. The identity of the proteins, along with number of peptide sequenced and sequence 
coverage, and searched results using public databases for known CaM-binding motif and known 
phosphorylation, is listed in Table 1. For each band, proteins are listed in the order of descending 
Mascot scores. We have identified a significant number of CaM-associated proteins including 
those previously uncharacterized such as EDD1, DNA-PKcs, and several DEAD/H box proteins. 
A large portion of these proteins contain known CaM binding motifs and known pSer/Thr/Tyr 
sites (Table 1). Some of these proteins (e.g. CDC42) may have indirect-binding to CaM, i.e. 
piggypacking to CaM binding proteins (e.g. IQGAP1 for CDC42) and await future 
characterization. Proteins are further categorized as below.  
Myosins. This is probably one of the best-characterized classes of CaM binding proteins. 
We identified myosin-9, myosin-6, myosin IE, and myosin IC. All of them contain IQ motif, 
which is a known Ca2+-independent CaM binding motif. Interestingly, myosin IC is the major 
component of Band 9 which showed clear upregulation of CaM binding with an increase in 
Thr/Ser phosphorylation (i.e., CLA treatment).  
 12
Heat shock proteins.  Most of the heat shock proteins we identified have known CaM-
binding motif. These include heat shock 90 kDa protein 1 (1-5-10 motif), heat shock 70 kDa 
protein 9B (IQ motif), heat shock cognate 71 kDa protein (unclassified motif), and heat shock 70 
kDa protein 1 (unclassified motif).  
Kinases and phosphatases. Of particular interest is DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs).  It is the catalytic subunit of PI-3 kinase DNA-PK, which has two 
other components Ku70 and Ku80 and plays an essential role in the repair of DNA double-strand 
breaks (DSBs). To our knowledge, there was no previous report on CaM-binding of DNA-PKcs. 
Interestingly a potential IQ motif can be mapped to the DNA-PKcs sequence. This implicates 
that CaM and hence calcium signaling might be involved in DNA repair. Consistently, we also 
identified DNA damage binding protein 1, which is involved in the repair of UV-damaged DNA. 
Others kinases include CaM-kinase II, CaM-kinase 1D, 6-phosphofructokinase type C, 6-
phosphofructo-2-kinase, and pyruvate kinase; while phosphatases include Ser/Thr protein 
phosphatase 5, Ser/Thr protein phosphatase 2A, and Ser/Thr protein phosphatase PP1.  
DEAD/H-box proteins. These are generally ATP-dependent DNA or RNA helicase and 
are involved in a variety of cellular processes. We identified multiple Ca2+/CaM-binding DEAD-
box proteins including DDX11, DDX3, DDX49, and DDX47. Using mRNA-display, Shen et al. 
identified DDX5, DDX21, and DDX57 as Ca2+/CaM-binding proteins.3 Therefore, RNA 
unwinding through DDX proteins may be regulated by Ca2+/CaM signaling.  
Ribosomal proteins. These proteins interact with RNA in the ribosome and are involved 
in translation. We have identified 40S ribosomal proteins S3, S4, S8, and S5. Using mRNA-
display, Shen et al. identified 40S ribosomal proteins S4, S8, S14, S15a, and 60S ribosomal 
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proteins L13a and L22.3 These results suggest that Ca2+/CaM may modulate ribosome assembly 
and translation through binding to ribosomal proteins.  
14-3-3 proteins. These are a large family of approximately 30 kDa acidic proteins which 
exist primarily as homo- and heterodimeric within all eukaryotic cells. They mainly bind proteins 
containing phosphothreonine or phosphoserine motifs.15 14-3-3 proteins can directly regulate the 
catalytic activity of the bound protein, or regulate protein-protein interactions and subcellular 
localization of the bound protein. We have identified 14-3-3 protein zeta/delta, theta and gamma. 
However, further studies are needed to determine whether these proteins bind directly to CaM or 
are just piggypacking with Ca2+/CaM-binding phosphoproteins. 
Other proteins. These include elongation factors such as elongation factor 1 and 
elongation factor Tu; RNA binding proteins 14, FUS and polymerase delta-interacting protein 3; 
structural proteins such as gamma actin, alpha/beta tubulin and F-actin capping protein; 
metabolic enzymes such as ubiquitin-protein ligase, tRNA synthetase, phosphate synthetase, 
ATP synthase, ADP/ATP translocase, enolase, phosphodiesterase 1A, and phosphate 
dehydrogenase; heterogeneous nuclear ribonucleoproteins (hnRNP) such as hnRNP U, M, K, H, 
and A2/B1; and DNA replication licensing factor MCM7 (CDC47). Other proteins not described 
are tabulated in detail in Table 1.  
To summarize, we have identified diverse classes of potentially Ca2+-dependent CaM 
binding proteins that are involved in a myriad of signaling pathways. We also observed the 
phosphorylation-dependent CaM binding of several proteins including EDD1 (Band 3) and 
IP3R1 (Band 4).  
CLA Treatment Significantly Reduced Calmodulin Bindings of EDD1, IP3R1, and DDX3    
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To further investigate the CaM binding patterns of EDD1 (Band 3), IP3R1 (Band 4), and 
DDX3 (Band 13) discovered in the silver stain gel (Figure 1B), Western blotting was performed 
using antibodies specific to human EDD1, IP3R1, DDX3, and actin respectively (Figure 2).  
Immunoblotting with anti-actin confirmed that equal amounts of total proteins were used in the 
CaM chromatography. Since actin does not binding directly to CaM, our results also indicated 
that the non-specific binding to Sepharose 4B beads during CaM chromatography was minimal. 
We showed that treatment with CLA or PV did not have any detectable effects on the expression 
levels of EDD1 and IP3R1 (Input, Figure 2A). However, the Western band of DDX3 was slightly 
up-shifted and had consistently higher intensity after CLA treatment but not PV treatment (Input, 
Figure 2A). DDX3 is an ATP-dependent RNA helicase and localizes mostly in the nucleus. The 
up-shift is consistent with its mobility shift after phosphorylation by CLA treatment. It is known 
that DDX3 shuttles between the nucleus and the cytoplasm in a XPO1-dependent manner.  
Therefore, the apparent increase in the band intensity is probably due to the translocation of 
DDX3 from Triton-X insoluble to Triton-X soluble fraction after its phosphorylation. The 
binding of EDD1, IP3R1, and DDX3 to calmodulin-sepharose in the presence of Ca2+ was 
dramatically reduced by CLA treatment when compared to the control (EDD1: 1.6 ± 1.9%, 
P<0.001, paired t-test, n=4; IP3R1: 50.2 ± 14.4%, P<0.001, paired t-test, n=4; DDX3: 32.3 ± 
8.8%, P<0.001, paired t-test, n=4), but not significantly affected by PV treatment (EDD1: 103.8 
± 8.0%, n=4; IP3R1: 112.1 ± 6.6%, n=4; DDX3: 96.7 ± 10.5%, n=4 ) (Figure 2B). Since CLA 
significantly increased global pSer/Thr levels as shown in Figure 1A, this suggested that the 
reduction of in vitro CaM binding of IP3R1, EDD1, and DDX3 are probably due to the elevation 
of their Ser/Thr phosphorylation in vivo. In presence of EGTA, the binding affinity between 
CaM and EDD1 and IP3R1 was dramatically decreased. But in the case of DDX3, 50% of its 
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CaM binding affinity remained in the presence of EGTA. Similarly, CLA but not PV treatment 
significantly reduced this Ca2+-independent CaM binding (CLA:  29.1 ± 4.5%; PV: 96.2 ± 
22.6%).  
 
Calmodulin Binding of IP3R1 was pSer/Thr-dependent in the Presence of Ca2+ 
To further confirm the pSer/Thr-dependent CaM binding of IP3R1, we utilized a novel 
combination of in vivo and in vitro assays (Figure 3). This strategy takes advantage of the 
dephosphorylation by phosphatases in vivo (in cells) as well as in vitro (in cell lysates). It is well 
known that phosphatases remain active after cell lysis. We used CLA and microcystin to inhibit 
Ser/Thr phosphatases in vivo and in vitro respectively, while used pervanadate to inhibit Tyr 
phosphatases in vitro. Cells were lysed using buffers containing different combinations of 
phosphatase inhibitors as described in the Experimental Procedures. As confirmed in Figure 3B, 
CLA treatment significantly increased the global pSer/Thr levels (all lanes in Ctrl vs. 
corresponding ones in CLA), but this increase was substantially reduced during overnight 
incubation if microcystin was absent in the lysis buffer (- and PV lanes vs. MC and PV+MC 
lanes). In the presence of Ca2+, the binding between CaM and IP3R1 is reduced after in vivo CLA 
treatment in a pair-wise comparison using the same lysis buffer (Figure 3A and 3C). The binding 
reduction between IP3R1 and CaM-sepharose was dramatically attenuated if microcystin was 
excluded from the lysis buffer. However, omission of pervanadate from the lysis buffer did not 
have substantial effects on the CaM binding of IP3R1 (Figure 3A and 3C). This clearly suggested 
that pSer/Thr, but not pTyr, of IP3R1 plays a major role in modulating its CaM binding. Further 
support for the dependence on pSer/Thr came from the alkaline phosphatase (AP lane) treatment 
experiments. Global dephosphorylation by alkaline phosphatase fully recovered the binding to 
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the basal level as in the control (Figure 3C). Interestingly, we also showed that the binding 
between IP3R1 and CaM was not dependent on IP3R1 phosphorylation in the absence of Ca2+ 
(EGTA lanes, Figure 3A and 3C), suggesting the complex interplay between Ca2+-dependnet and 
phosphorylation-dependent binding between IP3R1 and CaM.  
 
Phosphorylation-dependent binding between IP3R1 and calmodulin was regulated by 
staurosporine-sensitive kinase(s)  
To further determine which kinase(s) modulate pSer/Thr-dependent CaM binding of 
IP3R1, we have tested a series of kinase inhibitors (Figure 4). These inhibitors included: H-89, 
specific for PKA and less specific for PKG; chelerythrine (Che), specific for PKC; KT-5720 
(KT), specific for PKA and phosphorylase kinase; HA-1077 (HA), specific for Rho kinases; 
roscovitine (RO), specific for CDK 1, 2, and 5; and staurosporine (ST), nonspecific for pSer/Thr 
kinases.  
As shown in Figure 4, relative to the control, the CaM binding was significantly reduced 
in CLA alone (38.4 ± 7.5 %, n=7), reduced similarly with chelerythrine co-treatment (34.5 ± 
1.5%, n=3), recovered half-way with H-89 co-treatment (61.9 ± 13.1%, n=3), and recovered fully 
with staurosporine co-treatment (116.9 ± 4.9%, n=3). No significant effect was observed for KT, 
HA, and RO treatments (35.7 ± 13.5%, 35.5 ± 13.6%, 34.9 ± 16.0%, n=3).  At 50 µM, H-89 fully 
blocked PKA (IC50= 48 nM), PKG (IC50= 480 nM), and part of PKC (IC50= 31.7 µM). However, 
the CLA-induced reduction in CaM binding was only partially blocked. Since inhibiting PKC 
with chelerythrine did not show any significant effects, other pSer/Thr kinase(s) in addition to 
PKA/PKG were probably involved. This was confirmed in the case of co-treatment with 1 µM 
staurosporine.  
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Interestingly, dose dependent recovery was observed only for staurosporine ranging from 
10 nM to 1 µM (Figure 5). IC50 of staurosporine for PKA, PKC, and PKG is 7 nM, 0.7 nM, and 
8.5 nM, respectively. Our data strongly suggested that other staurosporine-sensitive kinases, but 
not PKA/PKC/PKG, play a critical role in mediating the CLA-induced reduction of CaM binding 
of IP3R1. We are actively pursuing the kinase(s) using RNA interference and overexpression of 
constitutively-active forms of potential kinase candidates.  
 
Phosphorylation-dependent binding between IP3R1 and CaM was regulated by 
phosphatase PP1 
PP2B, in addition to PP1, was previously implicated in the dephosphorylation of neuronal 
IP3R1 in neostriatal slices.16 To further examine which phosphatase modulate pSer/Thr-
dependent CaM binding of IP3R1, we treated HeLa cells with 20 nM calyculin A (CLA), an 
inhibitor for PP1 and PP2A; or 200 nM okadaic acid (OA), an inhibitor for PP1 and PP2A; or 10 
µM cyclosporine A (CsA), a PP2B inhibitor; or 10 µM FK506, another PP2B inhibitor. In 
contrast to CLA, CsA or FK506 treatment had no detectable effects on the CaM binding of 
IP3R1 (CsA: 97.6% ± 4.0%, n=3; FK506: 107.3% ± 9.9%, n=3) (Figure 6). This suggested that 
either the basal PP2B in HeLa cells is not involved in the dephosphorylation of IP3R1, or PP2B 
dephosphorylates pSer/Thr sites of IP3R1 that are remote to the CaM-binding motif(s). We also 
showed that OA had much smaller effects than CLA (OA: 100.6% ± 10.9%, n=3). CLA and OA 
have a similar potency for PP2A, but OA is 100-fold less potent for PP1 than CLA. Therefore, 
our results strongly suggested that PP1 is the major phosphatase mediating phosphorylation-
dependent CaM binding of IP3R1.  
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DISCUSSION 
It is increasingly clear that deciphering the complex mosaics of reversible protein 
assemblies in cellular pathways has become the central theme of systems biology. Cofactors such 
as metal ions regulate protein conformation and its functions. Given the critical role of protein 
phosphorylation and dephosphorylation in signal transduction of mammalian cells, it is essential 
to uncover the phosphorylation-dependent dynamic protein complexes in the context of 
biological pathways. In this study, we have showed that a new strategy “DPPC Trapping” is 
valuable in this endeavor. Using this strategy, we have successfully identified and verified 
multiple phosphorylation-dependent Ca2+/CaM complexes in HeLa cells. Subsequent detailed 
studies of IP3R1 have provided new insights into its in vivo regulation and biological functions.  
“DPPC Trapping” takes advantage of the drastic increase of global endogenous pTyr and 
pSer/Thr levels after in vivo treatment with respective phosphatase inhibitors (Figure 7). 
Subsequent in vitro affinity purification such as immunoprecipitation with antibodies or CaM 
beads will pull down corresponding complexes resembling those in vivo. Finally the binding 
proteins and their phosphorylation sites will be identified by mass spectrometry and/or Western 
blotting. In parallel, the phosphorylation-dependent binding under different conditions can be 
quantified. To identify low-abundant phosphorylated proteins, a two-step sequential 
immunoprecipitation process may be carried out in the future. For example, the above IP 
products can be eluted with a buffer containing 2 mM EGTA, and the CaM-binding pTyr 
proteins can be further enriched using PT-66 (anti-pTyr) antibody. This extra step may help to 
determine whether the binding to CaM is Tyr-phosphorylation-dependent or -independent. The 
major concern of “DPPC Trapping” may be whether phosphorylation-dependent complexes 
resulted from phosphatase inhibitors treatment recapitulate the in vivo complexes under 
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physiological conditions. Nevertheless, “DPPC Trapping” serves as a discovery-driven strategy 
to identify potential candidates as dynamic phosphoprotein complexes. Further evidence will 
come from the identification of the phosphorylation site(s), the mapping of the binding 
domain(s), and the validation of protein-protein interaction using other techniques such as 
surface plasmon resonance (SPR)-a label free and sensitive method used to detect molecular 
interactions in real-time.17 More insights into the phosphorylation-dependent binding will come 
from functional studies in the biological contexts.  
Calmodulin plays a fundamental role in calcium homeostasis and signaling. Oxidation 
and phosphorylation of calmodulin has been shown to influence its binding to Ca2+/CaM-
dependent proteins and result in important physiological consequences.10,18-20 However, no 
comprehensive studies on the phosphorylation status of Ca2+/CaM binding partners have been 
published. We hypothesize that phosphorylation modulates calcium homeostasis and signaling 
through three types of phosphorylation-dependent Ca2+/CaM complexes: phosphorylation-
disabling (p-disabling), phosphorylation-enabling (p-enabling), and phosphorylation-modulating 
(p-modulating) (Figure 7). Using “DPPC Trapping”, we have shown that binding of EDD1 and 
IP3R1 to CaM is phosphorylation-disabling and that of myosin IC is phosphorylation-enabling. 
EDD1 is an E3 ubiquitin-protein ligase which accepts the ubiquitin from an E2 ubiquitin-
conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted 
substrates. It may be involved in the regulation of DNA topoisomerase II binding protein 
(TopBP1) for the DNA damage response.21 To our knowledge, ours is the first report of the 
potential phosphorylation-dependent CaM binding of EDD1. As mentioned in the RESULTS 
section, we have also identified DNA-PKcs and DNA damage binding protein 1 as potential 
CaM-associated proteins. Taken together, Ca2+/CaM may play an important role in DNA damage 
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response and repair, through association with DNA-PKcs, DNA damage binding protein 1, and 
EDD1, in a Ca2+- and phosphorylation-dependent manner. Using mRNA display, Shen et al 
identified two CaM-binding deubiquitinating enzymes: ubiquitin C-terminal hydrolase UCHL5 
and ubiquitin specific protease-M USP-M.3 Therefore, Ca2+/CaM may also regulate ubiquitin-
proteasome pathways through differential bindings to ubiquitination-deubiquitination enzymes. 
We verified the pSer/Thr-dependent binding between DDX3 and CaM in a Ca2+-dependent 
manner. Since DDX3 is an ATP-dependent RNA helicase, our results suggested potential roles 
of Ca2+ signaling in RNA unwinding.  
IP3 receptors (IP3Rs) are critical Ca2+ release channels and respond to the second 
messenger IP3. IP3Rs are signal integrators that modulate a variety of cellular functions including 
contraction/excitation, secretion, gene expression, and cellular growth.22 They are localized to a 
number of cellular membranes including endoplasmic reticulum (ER), Golgi apparatus, 
nucleoplasmic reticulum (NR), and plasma membrane (PM). IP3R has three isoforms IP3R 1-3 
and IP3R1 contains binding sites for IP3, Ca2+, CaM, Gβ, RACK1, myosin, CARP, 4.1N protein 
and cytochrome C.22 IP3R1 is phosphorylated by multiple kinases including: PKA and PKG at 
Ser1589 and 1756 in rats (corresponding to Ser1598 and Ser1764 in human, respectively);23-25 
PKC and CaM-kinase II at distinct sites;26,27 AKT kinase at C-terminal tail S2681;28 Cyclin-
dependent kinase 1/cyclin B at Ser421 and Thr799;29,30 and tyrosine kinases Fyn at Tyr 353,31,32 
and Lyn.33 Protein phosphatase 1 and 2A form a macromolecular signaling complex with IP3R1 
and PKA and in turn regulate the phosphorylation and dephosphorylation of IP3R1.34 Extensive 
studies have demonstrated that calmodulin is a regulator of IP3R and influences the binding of 
IP3 to IP3R.35 For example, calmodulin was shown to bind to IP3R1 in a Ca2+-dependent manner 
and inhibit IP3-induced calcium release.36 More recently, a Ca2+-dependent CaM binding motif 
 21
(aa1574-aa1595) was mapped to the functionally-important regulatory domain of IP3R1;37 while 
the other Ca2+-independent CaM binding motif was mapped to its N-terminus.38 Using an in vitro 
kinase reaction between PKA and lysates from COS cells transfected with short and long forms 
of rat IP3R1, it was shown that CaM binding to the short form was reduced by 26% by in vitro 
PKA phosphorylation, while that to the long form was not significantly affected.39 The selective 
impairment was attributed to the preferential phosphorylation of Ser1589 in the short form, 
which is adjacent to the CaM binding domain.39,40 An earlier study has demonstrated that platelet 
IP3R1 can be directly phosphorylated by endogenous membrane-associated kinases as well as 
exogenous PKA, and the phosphorylation differentially affected the IP3-mediated Ca2+ release 
rate.41 In this study, we showed that pSer/Thr (but not pTyr) of IP3R1 significantly reduced its 
binding to Ca2+/CaM. We demonstrated that staurosporine-sensitive kinase(s), but not 
PKA/PKG/PKC, played a critical role in modulating this binding. We further showed that 
phosphatase PP1, but not PP2A or PP2B, was involved in the binding reduction.  IP3R1 contains 
both Ca2+-dependent (high affinity) and Ca2+-independent (low affinity) CaM binding domains. 
Our method, we believe, for the first time showed that the former is phosphorylation-dependent 
while the latter is not. We are currently in the process of mapping the critical pSer/Thr site(s) and 
identifying the corresponding kinase(s). Taken together, our data suggested that phosphorylation 
of IP3R1 inhibits its binding to CaM, promotes IP3-induced Ca2+ release, and regulates Ca2+ 
signaling and homeostasis in vivo. 
In conclusion, we have demonstrated the application of our “DPPC Trapping” method in 
identifying and characterizing Ca2+- and phosphorylation-dependent dynamic protein complexes 
in mammalian cells. If combined with other phosphoprotein and phosphopeptide enrichment 
techniques such as phospho-specific IP and IMAC 42, this method may serve as a general 
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strategy to identify the protein complexes, map the phosphorylation sites, identify the 
corresponding kinases and phosphatases, and functionally characterize dynamic protein 
complexes in vivo. 
 
ABBREVIATIONS:  CaM, calmodulin; IP3, inositol 1, 4, 5-trisphosphate; IP3R1, IP3 receptor 
1; DEAD box protein 3, DDX3; PKA, protein kinase A, cAMP-dependent protein kinase; PKC, 
protein kinase C; PKG, protein kinase G, cGMP-dependent protein kinase; PP1, PP2A and 
PP2B, protein phosphatase 1, 2A and 2B; LC/MS/MS, liquid chromatography-tandem mass 
spectrometry; Q-TOF, quadrupole/time-of-flight 
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FIGURE CAPTIONS 
Figure 1. Western blot analysis of HeLa cells after phosphatase inhibitors treatments (A) and 
silver staining of proteins bound to calmodulin-sepharose (B). (A) Cell lysates were separated on 
4-20% SDS-PAGE gels and blotted to nitrocellulose membranes. Total protein loaded per lane 
was 30 µg for cells either untreated (Ctrl), or treated with 20 nM calyculin A (CLA) for 1 hr, or 
100 µM pervanadate (PV) for 2 hr. The blots were probed with anti-pThr (left), anti-pTyr 
(center), and anti-actin (right), respectively. (B) The CaM chromatography was carried out in the 
presence of Ca2+ or EGTA, and the binding products from a total of 2 x 106 HeLa cells were 
compared in each lane. Gels were stained with silver nitrate. Twenty-two bands as labeled were 
cut out for mass spec analysis.  
 
Figure 2. The binding of EDD1, IP3R1, and DDX3 to calmodulin-sepharose. (A) A 
representative Western blot. (B) Quantitation of band intensity in the Western blots. The values 
were normalized to corresponding untreated controls and expressed as Mean ± S.D. (n=4). Error 
bar indicates the standard deviation (S.D.). HeLa cells were either untreated (Ctrl), or treated 
with 20 nM calyculin A (CLA) for 1 hr, or 100 µM pervanadate (PV) for 2 hr. 30 µg of total cell 
lysates were directly analyzed as input. The CaM chromatography was carried out in the 
presence of Ca2+ or EGTA, and the binding products from a total of 2 x 106 HeLa cells were 
compared in each lane. The blots were probed with anti-EDD1, anti-IP3R1, anti-DDX3, and anti-
actin (as negative control) antibody, respectively.  
 
Figure 3. pSer/Thr-dependent binding of IP3R1 to calmodulin-sepharose in a Ca2+-dependent 
manner. Representative Western blots of CaM binding products (A) and of corresponding total 
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cell lysates (B). (C) Quantitation of band intensity in the Western blots (A). The values were 
normalized to corresponding untreated controls with no inhibitors in the lysis buffer and 
expressed as Mean ± S.D. (n=4). Error bar indicates the standard deviation (S.D.). HeLa cells 
were either untreated (Ctrl) or treated with 20 nM calyculin A (CLA) for 1 hr, and then lysed 
using lysis buffers containing pervanadate (PV) only, or microcystin (MC) only, or both 
(PV+MC), or in the absence of inhibitors (-), or in the presence of alkaline phosphatase (AP, 50 
unit/ml) only. The CaM chromatography was carried out in the presence of Ca2+ or EGTA. The 
blots were probed with anti-IP3R1 (A) and p-Thr (B) antibody respectively.  
 
Figure 4. The effects of protein kinase inhibitors on the binding of IP3R1 to calmodulin-
sepharose.  (A) A representative Western blot of CaM binding products.  (B) Quantitation of the 
band intensity in the Western blots. The values were normalized to the untreated control and 
expressed as Mean ± SD. Error bar indicates standard deviation (S.D.). HeLa cells were either 
untreated, or treated with CLA alone, or treated with an inhibitor followed by the co-treatment 
with CLA. The data were analyzed for the control (Ctrl, n=7); 20 nM calycuin A alone (CLA, 
n=7); and inhibitor co-treatment with CLA plus 1 µM staurosporine (ST+CLA, n=3); 50 µM H-
89 (H-89+CLA, n=3); 2 µM chelerythrine (Che+CLA, n=3); 1 µM KT-5720 (KT+CLA, n=3); 5 
µM HA-1077 (HA+CLA, n=3); and 50 µM roscovitine (RO+CLA, n=3). The blot was probed 
with an anti-IP3R1 antibody.  
 
Figure 5. The effects of staurosporine (ST) on the binding of IP3R1 to calmodulin-sepharose in a 
dose-dependent manner. (A) A representative Western blot of CaM binding products. (B) 
Quantitation of the band intensity in the Western blots. The values were normalized to the 
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untreated control and expressed as Mean ± SD. Error bar indicates standard deviation (S.D.). 
HeLa cells were either untreated or treated with 20 nM calyculin A (CLA) alone, or co-treated 
with different concentrations of ST (10-1000 nM) as specified.  The blot was probed with an 
anti-IP3R1 antibody.  
 
Figure 6. The effects of protein phosphatase inhibitors on the binding of IP3R1 to calmodulin-
sepharose. (A) A representative Western blot of CaM binding products. (B) Quantitation of 
IP3R1 band intensities in the Western blots. The values were normalized to the untreated control 
and expressed as Mean ± SD (n=3). Error bar indicates standard deviation (S.D.). HeLa cells 
were either untreated (Ctrl), or treated with 20 nM calyculin A (CLA), or 200 nM okadaic acid 
(OA), 10 µM FK-506, or 10 µM cyclosporine A (CsA) for 1 hr. The blot was probed with an 
anti-IP3R1 antibody.  
 
Figure 7. A scheme showing the “DPPC Trapping” method and three kinds of phosphorylation-
dependent dynamic CaM complexes.  The basic strategy is to drastically shift the equilibrium 
towards endogenous phosphorylation of Ser, Thr, and Tyr at the global scale by inhibiting 
corresponding phosphatases in vivo. The phosphorylation-dependent including phosphorylation-
disabling (p-disabling), phosphorylation-enabling (p-enabling), and phosphorylation-modulating 
(p-modulating) complexes are then trapped in vitro in a Ca2+-dependent manner by calmodulin 
immunoprecipitation. Finally, the isolated calmodulin-binding proteins are separated by SDS-
PAGE and identified by LC/MS/MS. In parallel, the phosphorylation-dependent binding is 
visualized by silver staining and/or Western blotting. Protein complex candidates can be further 
verified and characterized through a combination of in vivo and in vitro assays. 
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Table 1: Potential Ca2+/CaM Binding Proteins isolated from HeLa cells 
Band 
No. 
 
 
 
 
Protein name 
No. 
of 
pepti
de 
seque
nced 
Sequ
ence 
cover
age 
Swiss- Prot 
accession 
No.  
Molecu
lar 
mass 
(kDa)  
Known 
CaM- 
binding  
motif a 
Kno
wn 
Phos
phor
ylatio
nc 
 
1 
 
Retinoblastoma-associated factor 600 
Plectin 1    
29 
7 
7% 
2% 
 
Q5T4S7 
Q15149 
573.8 
531.7 
- 
IQ 
- 
+ 
 
2 
 
DNA-dependent protein kinase catalytic 
subunit  (DNA-PKcs) 
 
3 1% P78527 469.1 IQ + 
3 
 
Ubiquitin-protein ligase EDD1 
 
18 10% O95071 309.4 IQ + 
4 
 
 
 
 
Inositol 1,4,5-trisphosphate receptor type 1 
 
Filamin-A  
Spectrin alpha chain 
Inositol 1,4,5-trisphosphate receptor type 3 
Spectrin beta chain 
CREB-binding protein (CBP) 
Centrosome protein Cep290 
 
40 
 
20 
11 
10 
2 
2 
2 
21% 
 
12% 
7% 
6% 
1% 
1% 
1% 
Q14643 
 
P21333 
Q13813 
Q14573 
Q01082 
Q92793 
Q66GS8 
313.9d 
 
280.7 
284.5 
304.0 
274.6 
265.3 
290.3 
 
1-14, 2 
Unclassified 
- 
- 
2 IQ  
IQ 
IQ 
- 
+ 
 
+ 
+ 
+b 
+ 
+ 
- 
5 
 
Myosin-9  
Girdin 
46 
4 
29% 
3% 
P35579 
Q3V6T2 
 
226.4 
215.9 
IQb 
Unclassified 
+ 
- 
 
 
6 
 
 
Ras GTPase-activating like protein IQGAP1 
TBC1 domain family member 4 
Bifunctional aminoacyl-tRNA synthetase  
Kinesin-like protein 2 
76 
7 
3 
2  
55% 
7% 
2% 
1% 
P46940 
O60343 
P07814 
Q9NS87 
 
189.2 
146.6 
163.1 
160.2 
4 IQb 
- 
IQ 
Unclassified 
+ 
+ 
+ 
- 
7 
 
 
 
 
Leucine-rich PPR-motif containing protein 
Neuropathy target esterase  
Myosin-6 
Carbamoyl-phosphate synthetase I  
Kinesin-like protein KIF1C 
Formin-like 1 protein 
Golgin subfamily A member 2  
14 
12 
8 
6 
7 
2 
1 
13% 
13% 
8% 
4% 
7% 
3% 
1% 
P42704 
O60859 
Q9UM54 
P31327 
O43896 
O95466 
Q08379 
145.2 
146.2 
148.7 
164.9 
123.1 
121.8 
111.7 
 
- 
- 
IQb 
- 
- 
- 
- 
- 
- 
+ 
- 
- 
- 
+ 
 
8 
 
Myosin IE 
DNA damage binding protein 1 
21 
3 
18% 
4% 
Q12965 
Q16531 
127.0 
126.9 
IQ 
- 
- 
- 
 
9 
 
 
Myosin IC 
Heterogeneous nuclear ribonucleoprotein U  
DDX11 protein 
 
31 
3 
3 
34% 
6% 
4% 
O00159 
Q00839 
Q86W62 
118.0 
90.4 
108.3 
 
3 IQb 
- 
- 
+ 
+ 
- 
10 
 
Heat shock 90 kDa protein 1, beta 2 3% Q5T9W7 83.3 1-5-10 - 
 
11 
DNA replication licensing factor MCM7  
6-phosphofructokinase type C 
15 
6 
22% 
9% 
P33993 
Q01813 
81.3 
85.6 
- 
- 
- 
+ 
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12 
 
 
 
 
RED protein  
Trifunctional enzyme alpha subunit 
78 kDa glucose-regulated protein 
Glycerol-3-phosphate dehydrogenase  
Long-chain-fatty-acid--CoA ligase 4 
Heterogeneous nuclear ribonucleoprotein M 
Lamin A/C 
Heat shock 70 kDa protein 9B 
11 
10 
7 
9 
6 
4 
3 
5 
 
27% 
20% 
17% 
18% 
11% 
7% 
6% 
8% 
 
Q13123 
P40939 
P11021 
P43304 
O60488 
P52272 
P02545 
Q6GU03 
 
65.6 
83.0 
72.3 
80.8 
79.2 
77.4 
74.1 
73.7 
 
- 
- 
IQ 
- 
- 
- 
- 
IQ 
- 
- 
- 
- 
- 
+ 
+ 
- 
 
13 
 
 
 
 
Heat shock cognate 71 kDa protein 
Heat shock 70 kDa protein 1 
RNA binding protein 14 
DEAD-box protein 3 
Melanoma-associated  antigen D2 
Calcium-binding mitochondrial carrier protein 
Aralar2 
 
17 
9 
8 
6 
6 
6 
 
34% 
23% 
15% 
12% 
16% 
16% 
 
P11142 
P08107 
Q96PK6 
O00571 
Q9UNF1 
Q9UJS0 
70.9 
70.0 
69.5 
73.1 
64.9 
74.2 
 
Unclassified 
Unclassified 
- 
- 
Unclassified 
- 
 
 
+ 
+ 
+b 
+ 
+ 
- 
14 
 
 
 
 
 
 
 
Calcium/calmodulin-dependent 3',5'-cyclic 
nucleotide phosphodiesterase 1A 
RNA-binding protein Fus 
Pyruvate kinase, isozymes M1/M2 
CaM-kinase II gamma chain 
Non-POU domain-containing octamer-
binding protein 
Heterogeneous nuclear ribonucleoprotein K 
Nucleolar complex protein 4 homolog 
PAP associated domain containing 1 
Phenylalanyl-tRNA synthetase alpha chain 
COP9 signalosome complex subunit 1 
D-3-phosphoglycerate dehydrogenase 
Serine/threonine protein phosphatase 5 
SH2D4A protein 
 
8 
 
9 
6 
3 
5 
 
3 
3 
2 
1 
2 
3 
1 
2 
 
20% 
 
16% 
16% 
8% 
15% 
 
10% 
9% 
5% 
2% 
4% 
6% 
4% 
5% 
P54750 
 
P35637 
P14618 
Q13555 
Q15233 
 
P61978 
Q9BVI4 
Q6P7E5 
Q9Y285 
Q13098 
O43175 
P53041 
Q5XKC1 
 
61.1 
 
53.4 
57.8 
62.6 
54.2 
 
51.0 
58.5 
66.2 
57.4 
53.4 
56.5 
56.9 
52.7 
1-12  
 
- 
- 
- 
- 
 
- 
- 
- 
Unclassified 
- 
IQ 
- 
- 
- 
 
+ 
- 
+ 
- 
 
+b 
- 
- 
- 
- 
- 
- 
- 
 
15 
 
 
 
 
ATP synthase alpha chain 
ATP synthase beta chain 
Probable ATP-dependent RNA helicase 
DDX49 
Seryl-tRNA synthetase  
Plasminogen activator inhibitor 1 RNA-
binding protein 
 
6 
3 
5 
 
2 
1 
 
15% 
8% 
15% 
 
6% 
4% 
 
P25705 
P06576 
Q9Y6V7 
 
Q9NP81 
Q8NC51 
 
59.8 
56.6 
54.2 
 
58.3 
44.9 
Unclassified 
- 
- 
 
IQ 
IQ 
+ 
- 
- 
 
- 
+ 
16 
 
 
 
 
 
 
 
Tubulin beta 
Tubulin alpha-6 chain 
Tubulin beta-6 chain 
NOL1/NOL2/SUN domain family, member 5, 
isoform 1 
Chromatin assembly factor 1 subunit C  
RuvB-like 2 
CaM-kinase II delta chain 
Heterogeneous nuclear ribonucleoprotein H 
Serine/threonine protein phosphatase 2A, 55 
kDa regulatory subunit B, alpha isoform 
SWI/SNF-related matrix-associated actin-
16 
10 
8 
10 
 
2 
2 
1 
1 
2 
 
1 
40% 
33% 
20% 
24% 
 
6% 
5% 
2% 
3% 
5% 
 
3% 
P07437 
Q9BQE3 
Q9BUF5 
Q96HT9 
 
Q09028 
Q9Y230 
Q13557 
P31943 
P63151 
 
Q969G3 
49.7 
49.9 
49.9 
50.4 
 
47.5 
51.0 
56.3 
49.1 
51.7 
 
46.6 
- 
- 
- 
- 
 
- 
- 
1-5-10 
- 
- 
 
IQ 
+ 
- 
- 
+ 
- 
- 
+ 
+ 
- 
- 
 
- 
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dependent regulator of chromatin E1 
Probable ATP-dependent RNA helicase 
DDX47 
Alpha-enolase 
6-phosphofructo-2-kinase  
 
1 
 
3 
1 
 
3% 
 
9% 
2% 
 
Q9H0S4 
 
P06733 
Q5VVQ3 
 
 
50.6 
 
47.0 
54.4 
 
- 
 
- 
- 
 
- 
 
+ 
- 
 
17 
 
 
 
 
 
Elongation factor 1-alpha 1 
Polymerase delta-interacting protein 3 
Trifunctional enzyme beta subunit 
Elongation factor Tu 
Protein TFG 
Methionine adenosyltransferase II, alpha 
Splicing factor 3B subunit 4 
Elongation factor 1-gamma 
Eukaryotic translation initiation factor 4A, 
isoform 2 
 
8 
4 
3 
2 
3 
1 
1 
1 
1 
 
20% 
15% 
6% 
5% 
9% 
3% 
3% 
2% 
3% 
 
P68104 
Q9BY77 
P55084 
P49411 
Q92734 
Q53SP5 
Q15427 
P26641 
Q53XJ6 
 
50.1 
46.1 
51.4 
49.5 
43.4 
43.7 
44.4 
49.9 
46.4 
- 
- 
IQ 
- 
- 
- 
- 
Unclassified 
Unclassified 
+ 
+ 
- 
- 
- 
- 
+ 
- 
- 
 
 
18 
 
 
 
Gamma-actin 
Stomatin-like protein 2 
RNA (guanine-9-) methyltransferase domain 
containing 1 (HNYA) 
Calcium/calmodulin-dependent protein 
kinase type 1D 
 
14 
6 
5 
 
2 
47% 
30% 
15% 
 
8% 
P63261 
Q9UJZ1 
Q9NRG5 
 
Q8IU85 
41.8 
38.5 
47.3 
 
42.9 
 
- 
- 
- 
 
1-14 
- 
+ 
- 
 
+ 
 
 
19 
 
 
 
 
 
Annexin A2 
Protein kinase C, delta binding protein 
Glyceraldehyde-3-phosphate dehydrogenase 
BLOCK 23 
F-actin capping protein alpha-1 subunit 
Heterogeneous nuclear ribonucleoproteins 
A2/B1 
Ser/Thr protein phosphatase PP1-alpha 
Protein C20orf77 
L-lactate dehydrogenase A chain 
11 
7 
5 
4 
3 
2 
 
1 
1 
1 
33% 
45% 
17% 
14% 
14% 
7% 
 
5% 
4% 
4% 
 
P07355 
Q969G5 
P04406 
Q8NHW5 
P52907 
P22626 
 
P62136 
Q9NQG5 
P00338 
 
38.5 
27.6 
35.9 
34.4 
32.9 
37.4 
 
37.5 
36.9 
36.6 
Unclassified 
IQ 
- 
- 
- 
- 
 
- 
- 
- 
+ 
- 
+ 
- 
- 
+ 
 
+ 
+ 
+ 
 
20 
 
 
ATP synthase gamma chain 
Prostaglandin E synthase 2 (Truncated) 
40S ribosomal protein S3 
 
5 
2 
3 
 
25% 
15% 
16% 
 
P36542 
Q9H7Z7 
P23396 
 
33.0 
29.2 
26.7 
 
- 
- 
- 
- 
- 
+ 
 
 
 
 
 
21 
 
 
 
 
 
 
 
40S ribosomal protein S4, X isoform 
ADP/ATP translocase 2 
14-3-3 protein zeta/delta 
Pyrroline-5-carboxylate reductase-like 
UPF0082 protein PRO0477 
Protein C21orf70 
14-3-3 protein theta 
Ribosomal protein S8 
14-3-3 protein gamma 
Osteoclast stimulating factor 1 variant 
Cytochrome C-1 
Proteasome subunit alpha type 7 
SCO1 protein homolog 
6 
6 
4 
3 
4 
2 
2 
1 
1 
1 
1 
1 
1 
18% 
18% 
22% 
13% 
28% 
11% 
13% 
6% 
5% 
5% 
4% 
5% 
8% 
 
P62701 
P05141 
P63104 
Q96HX4 
Q9BSH4 
Q9NSI2 
P27348 
Q5JR95 
P61981 
Q5W126 
Q5U062 
O14818 
O75880 
29.5 
32.8 
27.8 
28.6 
32.5 
25.5 
27.8 
21.9 
28.2 
23.8 
35.4 
27.9 
33.8 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
+ 
- 
- 
- 
+ 
- 
- 
- 
- 
- 
- 
 
 Cell division control protein 42 homolog 4 24% P60953 21.3 - + 
 32
 33
22 
 
 
(CDC42) 
40S Ribosomal protein S5 
Rho family GTPase Chp 
 
 
3 
1 
 
22% 
4% 
 
P46782 
Q96L33 
 
22.7 
26.2 
 
- 
- 
 
 
- 
- 
 
a Note: Searched through: http://calcium.uhnres.utoronto.ca  
b Note: Searched through: http://us.expasy.org/sprot/  
c Note: Searched through: http://www.phosphosite.org 
d Note: Theoretical molecular weight for the full length IP3R1 (i.e. long form) 
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